Vol. 12, Issue 6 (2023)

Author(s):
Anushka Verma, Anjana Sharma and Suman Tapryal

Abstract:
Cases of chikungunya have been reported worldwide however the African, Asian, and the Indian subcontinents are the most affected areas. The virus once enters the host body, replicates in the midgut of a mosquito, and infect human until it dies. These mosquitoes mostly bite during the day and complete their life cycle in settled water bodies. Other than symptoms, serological tests like Elisa and RT-PCR are used as diagnostic tools. As there is no vaccination available for chikungunya now, the only treatment that exists is for relieving the symptoms. An attempt was tried to create a vaccine candidate for chikungunya by fusing the coat glycoprotein E2 with the constant region of the heavy chain of IgG. The competent E-coli cells transferred with E2 cloned pET28b vector and induced it with IPTG to express the protein. This protein was checked for solubility in pellet and supernatant and was further purified by phosphate buffer and refolded by SP Sepharose chromatography. This protein would be a potential vaccine candidate for chikungunya treatments.